Ileum-Targeted Sequestrant for Metabolic Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for metabolic diseases such as alcoholic hepatitis and non-alcoholic steatohepatitis are inadequate in addressing the underlying causes of liver inflammation and insulin resistance, as they primarily target specific cellular components rather than the upstream sources of inflammation.
Innovation Solution
The development of PASA (Pathogen Adsorption and Sequestration Agents) therapy, which involves the use of high-molecular-weight copolymeric sequestrants specifically designed to target and sequester endotoxins and other pathogen-associated molecular patterns (PAMPs) in the distal region of the small intestine, thereby blocking the intestinal source of inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional treatments target specific cellular components (receptors, enzymes), then treatment specificity is improved, but the ability to address upstream sources of inflammation (intestinal endotoxins) deteriorates
Solution Approach 1:
The patent extracts and removes the harmful factor (intestinal endotoxins) at its source rather than treating downstream effects. By using sequestrants that bind to endotoxins in the distal small intestine, the treatment removes the harmful substance before it can enter circulation and cause inflammation, directly addressing the upstream source of the problem.
Solution Approach 2:
The patent introduces an intermediary substance (sequestrant) that mediates between the harmful endotoxin and the body's immune system. The sequestrant binds to endotoxins, forming a complex that is then excreted, preventing direct interaction between endotoxins and immune cells, thus reducing inflammation without requiring direct targeting of cellular components.
2Quantity of substance
If high-molecular-weight copolymeric sequestrants are used to sequester endotoxins, then endotoxin binding capacity is improved, but gastrointestinal side effects (diarrhea, abdominal pain) worsen
Solution Approach 1:
The patent applies local quality by targeting the sequestrant delivery specifically to the distal small intestine where endotoxin concentration is highest. Using pH-sensitive coatings that dissolve at intestinal pH, the treatment concentrates the sequestrant action where it is most needed (at the endotoxin source) rather than distributing it throughout the entire GI tract, thereby reducing unnecessary GI side effects.
Solution Approach 2:
The patent utilizes parameter changes by employing pH-sensitive coatings that alter their solubility based on pH conditions. The coating remains intact in the acidic stomach environment but dissolves in the neutral-to-alkaline intestinal environment, enabling controlled release of the sequestrant at the appropriate location and time to maximize endotoxin binding while minimizing GI disturbance.
3Loss of substance
If sequestrants are released in the upper small intestine, then absorption is minimized, but endotoxin sequestration efficiency deteriorates since endotoxins are richest in the distal region
Solution Approach 1:
The patent applies dynamics by using pH-sensitive coatings that dynamically change their solubility state based on the environmental pH. The coating transitions from an insoluble protective barrier in the stomach to a soluble form in the intestine, enabling the sequestrant to be released precisely when and where it is most needed (in the distal small intestine) rather than being released too early in the upper intestine.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
PASA therapy effectively reduces plasma endotoxin levels, suppresses systemic and hepatic inflammation, and improves metabolic disorders by addressing the root cause of inflammation, offering a novel and effective approach for treating metabolic and liver diseases.
Implementation Method 1
The API is non-digestible and non-absorbable in the digestive tract of the subject. The sequestrant specifically binds to PAMPs, such as endotoxins and CpG-DNA.
Data Source
AI summary
A method of treating a subject having a metabolic disorder, caused or promoted by pathogen-associated molecular patterns (PAMPs) derived from intestinal sources, including: administering to the subject a specially formulated drug that is targeted to deliver a sequestrant into the distal region of small intestine for sequestration of PAMPs including endotoxins or CpG-DNA derived from gut microbes. The sequestrant binds to the PAMPs to form a sequestrant-PAMP complex; and the sequestrant-PAMP complex is eliminated from the digestive tract along with the rest of digestive contents.